Farallon Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Farallon Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-8,500,000	Closed	-$394M	–	120
2019 Q2	$394M	Buy	8,500,000 +3,000,000	+55%	+$84.2M	2.56%	9
2019 Q1	$134M	Sell	5,500,000 -250,000	-4%	-$5.2M	1.01%	31
2018 Q4	$81.9M	Buy	5,750,000 +625,000	+12%	+$9.48M	0.6%	37
2018 Q3	$77.9M	Buy	5,125,000 +475,000	+10%	+$7.28M	0.46%	40
2018 Q2	$78M	Buy	4,650,000 +1,555,000	+50%	+$24.7M	0.48%	40
2018 Q1	$50.5M	Buy	+3,095,000	New	+$49.6M	0.35%	51

Other funds holding ARRY

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Farallon Capital Management's ARRY Position: Q3 2019 in Review

Farallon Capital Management sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 8,500,000 shares — an estimated $394M sold.

Farallon Capital Management first reported a position in ARRY in Q1 2018 and held it in 6 quarters. The position peaked at $394M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

Farallon Capital Management reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
Farallon Capital Management sold 8,500,000 Array Biopharma Inc shares in Q3 2019, an estimated $394M.
Farallon Capital Management first reported a position in Array Biopharma Inc in Q1 2018 and held it in 6 quarters.
Farallon Capital Management's Array Biopharma Inc position peaked at $394M in Q2 2019.
1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Farallon Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.